C Diff Drug Development

After a recent $106.5m fundraise, the designation marks another milestone for the company set to start a Phase III study later this year.

The increased research and development activities for developing and launching new drugs are expected to fuel growth in the Clostridium difficile infection...

Previously, 1-((4-(4-bromophenyl)-1H-imidazol-2-yl)methyl)-3-(5-(pyridin-2-ylthio)thiazol-2-yl)urea bearing a p-bromine substitution was shown to possess selective inhibitory activity against the Clostridioides difficile enoyl-acyl carrier protein (ACP) reductase II enzyme, FabK. Inhibition of CdFab …

Previously, 1-((4-(4-bromophenyl)-1H-imidazol-2-yl)methyl)-3-(5-(pyridin-2-ylthio)thiazol-2-yl)urea bearing a p-bromine substitution was shown to possess selective inhibitory activity against the Clostridioides difficile enoyl-acyl carrier protein (ACP) reductase II enzyme, FabK. Inhibition of CdFab …

A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.

Lumen Bioscience Receives Fast Track Designation from U.S. FDA for LMN-201 - read this article along with other careers information, tips and advice on BioSpace

LMN-201, an oral biologic drug developed by Lumen Bioscience, has received Fast Track Designation from the FDA. The drug combines therapeutic proteins to neutralize the bacterium and toxin that cause C difficile infection.

LMN-201 combines 4 therapeutic proteins that act synergistically.

The increased research and development activities for developing and launching new drugs are expected to fuel growth in the Clostridium difficile infection treatment market by providing an alternative treatment. The companies developing the potential therapies in the last stage of development include Pfizer, Seres Therapeutics, Summit Therapeutics, and others.New York, USA, May 03, 2023 (GLOBE NEWSWIRE) -- Clostridium difficile Infections Pipeline Analysis Demonstrates 18+ Key Companies at the H

Increasing antimicrobial resistance among Gram-positive pathogens and pathogenic fungi remains one of the major public healthcare threats. Therefore, novel antimicrobial candidates and scaffolds are critically needed to overcome resistance in Gram-positive pathogens and drug-resistant fungal pathoge …

Bublitz et al. identified that the natural product chlorotonil A (ChA) has antimicrobial activity against Clostridioides difficile, preventing relapsing disease in a mouse model. Favorable properties of ChA synergize for this protective effect, including reduced microbiome damage, preservation of colonization resistance, and prevention of vegetative cell outgrowth from spores.

New York, USA, May 03, 2023 (GLOBE NEWSWIRE) -- Clostridium difficile Infections Pipeline Analysis Demonstrates 18+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight The

After a recent $106.5m fundraise, the designation marks another milestone for the company set to start a Phase III study later this year.

A team of biochemists at the University of Notre Dame has found a possible new way to treat patients infected with Clostridioides difficile, a type of bacteria that causes serious gastrointestinal problems. In their study, reported in Proceedings of the National Academy of Sciences, the group searched medical databases for antibacterial molecules that might work better for patients with C. difficile infections.

Dublin, May 09, 2023 (GLOBE NEWSWIRE) -- The "Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By...

Clostridium difficile kills 13,000 people each year in the US alone. A new antibiotic tested in mice works better than our first-line treatments against infection – and prevents reinfection too

CAMBRIDGE, Mass., May 08, 2023--Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI). Fast Track designation is a process designed to facilitate the development and expedite the

Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

A novel oral microbial therapy under development by Vedanta Biosciences reduced the risk of recurrence of Clostridioides difficile infection in a phase 2 clinical trial.

The increased research and development activities for developing and launching new drugs are expected to fuel growth in the Clostridium difficile infection...

J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.

Small-molecule inhibitors offer many advantages for manipulating the gut microbiome, both as tool compounds and as potential therapeutics. This Review highlights recent examples of inhibitors that target gut bacterial enzymatic activity as well as the challenges and opportunities associated with their design and development.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.

This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.

A novel oral microbiome-directed therapy called VE303 successfully prevented recurrent Clostridioides difficile infection in adults at high risk for recurrence, researchers found.

Seres Therapeutics took 12 years to develop one of the first microbiome drugs in the U.S. Here's a timeline of major milestones and setbacks along the way.

Seres Therapeutics (MCRB) shares surged to reach a four month high on Monday as the company awaits the FDA decision on its lead candidate SER-109. Read more here.

This clinical trial compares the efficacy of 2 different doses of VE303, a defined bacterial consortium of 8 strains of commensal Clostridia, and placebo in preventing recurrence of Clostridioides difficile infection among adults at high risk.

J.P. Morgan has initiated Seres Therapeutics (MCRB) with a neutral rating saying that it will take time for SER-109 to have its reimbursement take place.